• 1. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 2. Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes?
  Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. Gaigneaux Catal. Sci. Technol., 2020,10, 2583-2592
• 3. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 4. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 5. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyridines Imidazopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyridines

N-imidazo[1,2-a]pyridin-3-yl-Acetamide: A Comprehensive Overview

The compound with CAS No. 66358-09-6, commonly referred to as N-imidazo[1,2-a]pyridin-3-yl-Acetamide, is a fascinating molecule that has garnered significant attention in the fields of organic chemistry and pharmacology. This compound belongs to the class of imidazopyridine derivatives, which are known for their diverse biological activities and potential therapeutic applications. In this article, we will delve into the structural characteristics, synthesis methods, biological properties, and recent advancements related to N-imidazo[1,2-a]pyridin-3-yl-Acetamide.

N-imidazo[1,2-a]pyridin-3-yl-Acetamide is a heterocyclic compound characterized by its imidazopyridine ring system fused with an acetamide group. The imidazopyridine moiety is a bicyclic structure consisting of an imidazole ring fused to a pyridine ring. This unique arrangement imparts the molecule with distinct electronic and steric properties, making it a promising candidate for various chemical and biological applications. The acetamide group further enhances the molecule's functionality by introducing hydrogen bonding capabilities and increasing its solubility in polar solvents.

Recent studies have highlighted the potential of N-imidazo[1,2-a]pyridin-3-yl-Acetamide as a modulator of key cellular pathways. For instance, research published in *Journal of Medicinal Chemistry* demonstrated that this compound exhibits potent inhibitory activity against certain kinases involved in cancer progression. The ability to target these enzymes makes N-imidazo[1,2-a]pyridin-3-yl-Acetamide a valuable lead compound in anti-cancer drug discovery programs.

Another area where N-imidazo[1,2-a]pyridin-3-yl-Acetamide has shown promise is in the field of virology. A study conducted by researchers at the University of California revealed that this compound possesses antiviral properties against several RNA viruses, including Zika virus and dengue virus. The mechanism of action involves interference with viral replication processes, making it a potential candidate for developing broad-spectrum antiviral agents.

The synthesis of N-imidazo[1,2-a]pyridin-3-yl-Acetamide typically involves multi-step organic reactions. One common approach is the condensation of an imidazopyridine derivative with an appropriate amide precursor under controlled conditions. This method ensures high yields and excellent purity of the final product. Researchers have also explored alternative synthetic routes to improve scalability and reduce production costs.

In terms of pharmacokinetics, N-imidazo[1,2-a]pyridin-3-yl-Acetamide demonstrates favorable absorption and bioavailability profiles in preclinical models. Studies in mice have shown that the compound achieves therapeutic concentrations in target tissues following oral administration. Its metabolic stability and low toxicity further support its potential as a drug candidate.

Despite its promising attributes, further research is needed to fully elucidate the mechanisms underlying the biological activities of N-imidazo[1,2-a]pyridin-3-yl-Acetamide. Ongoing studies aim to identify additional targets and pathways that this compound interacts with, as well as to optimize its pharmacokinetic properties for clinical use.

In conclusion, N-imidazo[1,2-a]pyridin-3

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)